Jiangsu Hengrui Medicine (600276 CH): ADC Drug Approval Presents Long-Term Opportunity
​Jiangsu Hengrui receives conditional approval for Trastuzumab Rezetecan for NSCLC. In 1Q25, the company reported sales growth of 20%. Innovative...
440 Views
APAC Healthcare Weekly (June 1)- Eisai, Daiichi, Samsung Bio, SK Bioscience, CSPC, Hengrui Pharma
​Eisai's Dayvigo approved in China. Daiichi Sankyo withdrew BLA in US. Samsung Bio secures CMO contracts. SK Bioscience expands vaccine...
550 Views
CSPC Pharmaceutical (1093 HK): Finished Drugs Drag 1Q25; Out Licensing And New Launches To Be Key
​CSPC Pharmaceutical's 1Q25 revenue dropped 22% YoY, but operating margin remained stable. License and collaboration for pipeline products should...
596 Views
China Healthcare Weekly (May.18) - Trump to Lower US Drug Prices, Thoughts on Hengrui's IPO Pricing
Hengrui's HK IPO debut is strong, driven by positive sentiment for AH listing and the small IPO size (225 million circulating shares). Investors...
720 Views
Jiangsu Hengrui Pharma A/H Trading - Strong Demand for Quality Asset, but Is Pricey
Jiangsu Hengrui Pharmaceuticals (1276 HK) (JHP, 600276 CH ), a China-based pharmaceutical company, raised around US$1.5bn in its H-share listing....
417 Views